Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study

Table 4 The adjusted impact of DMTs on SARS-CoV-2 neutralizing Ab, anti-nucleocapsid IgG, and anti-spike IgG

Variables	Neutralizing Ab		Anti-nucleocapsid IgG		Anti-spike IgG
Variables	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
DMT
None-receivers	ref	----	ref	----	ref	----
IFN-β	0.19 (0.02, 1.78)	0.146	0.31 (0.04, 2.37)	0.262	0.42 (0.06, 3.05)	0.388
Dimethyl fumarate	0.49 (0.05, 5.29)	0.560	0.49 (0.05, 4.41)	0.525	1.07 (0.11, 10.08)	0.950
Glatiramer acetate	1.03 (0.09, 11.92)	0.978	0.72 (0.07, 7.08)	0.780	1.24 (0.12, 12.29)	0.855
Anti-CD20s	0.18 (0.02, 1.44)	0.106	0.12 (0.02, 0.85)	0.034	0.24 (0.04, 1.48)	0.123
Fingolimod	0.04 (0.00, 0.51)	0.013	0.07 (0.01, 0.64)	0.019	0.11 (0.01, 0.96)	0.045
Teriflunomide	NA	1.000	NA	1.000	NA	1.000
Natalizumab	0.00 (0.00, 0.00)	0.999	0.07 (0.00, 1.35)	0.079	0.51 (0.04, 6.84)	0.614

Note: Multivariate logistic regression was used to evaluate the impact of each DMT on dichotomous Ab responses. The model was adjusted for variables, including age, sex, MS phenotype, EDSS score, disease duration, and vaccination-Ab titration interval. Abbreviations: Antibody: Ab, CI: confidence interval; DMT: disease-modifying therapies; IFN: interferon; IgG: immunoglobulin G; OR: odds ratio; P: probability value; ref: reference; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

ISSN: 1471-2377